A comparison between persistence to therapy in ALLHAT and in everyday clinical practice: A generalizability issue

Canadian Journal of Cardiology

Volumn 20, Issue 4, 2004, Pages 417-421

  Cardinal, Héloise ^a   Monfared, Amir Abbas Tahami ^a   Dorais, Marc ^a   LeLorier, Jacques ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Drugs; Health economics; Hypertension

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; THIAZIDE DIURETIC AGENT;

ANTIHYPERTENSIVE THERAPY; ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; DATA BASE; DRUG INDUSTRY; HEART INFARCTION; HUMAN; HYPERTENSION; MEDICAL LITERATURE; MEDICAL RESEARCH; MEDLINE; PATIENT COMPLIANCE; PRESCRIPTION; RESOURCE MANAGEMENT; TREATMENT OUTCOME;

EID: 2342589531     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-97.
2. Conlin PR, Gerth W, Fox J, Roehm J, Boccuzzi S. Four-year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other antihypertensive drug classes. Clin Ther 2001;23:1999-2010.
3. Kostis J, Davis R, Cutler J, et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA 1997;278:212-6.
4. Kostis J, Davis R, Cutler J, et al. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA 1991;265:3255-65.
5. Dahlof B, Lindholm L, Hanson L, Schersten B, Ekbom T, Wester PO. Morbidity and mortality in the Swedish Trial in Old patients with Hypertension (STOP-Hypertension). Lancet 1991;338:1281-5.
6. Marentette MA, Gerth WC, Billings DK, Zarnke KB. Antihypertensive persistence and drug class. Can J Cardiol 2002;18:649-56.
7. Chaput AJ. Persistency with angiotensin receptor blockers versus other antihypertensives using the Saskatchewan database. Can J Cardiol 2000;16(Suppl F):194F.
8. Conlin PR, Fox J, Gerth W, Boccuzzi S. Losartan/angiotensin II antagonists have greater persistence than other antihypertensive agents/classes. Am J Hypertens 2002;15(Suppl I):29A. (Abst)
9. Bloom B. Continuation of initial antihypertensive medication after 1 year of therapy. Clin Ther 1998;20:671-81.
10. Hasford J, Mimram A, Simons WR. A population based cohort study of persistence in newly diagnosed hypertensive patients. J Hum Hypertens 2002;16:569-75.
11. Jones JK, Gorkin L, Lian JF, Staffa JA, Fletcher AP. Discontinuation of and changes in treatment after start of new course of antihypertensive drugs: A study of a United Kingdom population. BMJ 1995;311:293-5.
12. Pham HT, Gause D, Frech FH, et al. Discontinuation, switching and adding among hypertensive drug classes. Am J Hypertens 2001;14(Suppl I):112A. (Abst)
13. Wogen J, Krejilick CA, Livornese RC, et al. A population-based study of compliance and persistence with cardiovascular agents used in hypertension management. Am J Hypertens 2001;14(Suppl I):112A. (Abst)
14. Caro J, Speckman J, Salas M, Raggio G, Jackson J. Effect of initial drug choice on persistence with antihypertensive therapy: The importance of actual practice data. CMAJ 1999;160:41-6.
15. McCombs JS, Nichol MB, Newman CM, Sclar DA. The costs of interrupting antihypertensive drug therapy in a Medicaid population. Med Care 1994;32:214-26.
16. Degli Esposti L, Degli Esposti E, Valpiani G, et al. A retrospective, population based analysis of persistence with antihypertensive therapy in primary care practice in Italy. Clin Ther 2002;24:1347-57.
17. Jokisalo E, Enlund H, Halonen P, Takala J, Kumpusalo E. Factors related to poor compliance with antihypertensive drug therapy. J Hum Hypertens 2002;16:577-83.
18. Andrade JP, Vilas-Boa F, Chagas H, Andrade M. Epidemiological aspects of adherence to the treatment of hypertension. Arq Bras Cardiol 2002;79:375-84.
19. Joint National Comittee on Prevention, diagnosis and treatment of hypertension. Arch Intern Med 1997;157:2413-46.